- Research article
- Open Access
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
BMC Cancer volume 9, Article number: 411 (2009)
c-Met is a tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF/SF), and both c-Met and its ligand are expressed in a variety of tissues. C-Met/HGF/SF signaling is essential for normal embryogenesis, organogenesis, and tissue regeneration. Abnormal c-Met/HGF/SF signaling has been demonstrated in different tumors and linked to aggressive and metastatic tumor phenotypes. In vitro and in vivo studies have demonstrated inhibition of c-Met/HGF/SF signaling by the small-molecule inhibitor PHA665752. This study investigated c-Met and HGF expression in two neuroblastoma (NBL) cell lines and tumor tissue from patients with NBL, as well as the effects of PHA665752 on growth and motility of NBL cell lines. The effect of the tumor suppressor protein PTEN on migration and proliferation of tumor cells treated with PHA665752 was also evaluated.
Expression of c-Met and HGF in NBL cell lines SH-EP and SH-SY5Y and primary tumor tissue was assessed by immunohistochemistry and quantitative RT-PCR. The effect of PHA665752 on c-Met/HGF signaling involved in NBL cell proliferation and migration was evaluated in c-Met-positive cells and c-Met-transfected cells. The transwell chemotaxis assay and the MTT assay were used to measure migration and proliferation/cell-survival of tumor cells, respectively. The PPAR-γ agonist rosiglitazone was used to assess the effect of PTEN on PHA665752-induced inhibition of NBL cell proliferation/cell-survival and migration
High c-Met expression was detected in SH-EP cells and primary tumors from patients with advanced-stage disease. C-Met/HGF signaling induced both migration and proliferation of SH-EP cells. Migration and proliferation/cell-survival were inhibited by PHA665752 in a dose-dependent manner. We also found that induced overexpression of PTEN following treatment with rosiglitazone significantly enhanced the inhibitory effect of PHA665752 on NBL-cell migration and proliferation.
c-Met is highly expressed in most tumors from patients with advanced-stage, metastatic NBL. Furthermore, using the NBL cell line SH-EP as a model, PHA665752 was shown to inhibit cMet/HGF/SF signaling in vitro, suggesting c-Met inhibitors may have efficacy for blocking local progression and/or metastatic spread of c-Met-positive NBL in vivo. These are novel findings for this disease and suggest that further studies of agents targeting the c-Met/HGF axis in NBL are warranted
Children with metastatic neuroblastoma (NBL) who are older than 12 months at diagnosis typically have a poor outcome despite modern multimodal therapy. In most of these patients, the tumor has unfavorable biological characteristics such as MYCN oncogene amplification, deletions of the short arm of chromosome 1, deletions of 11q, expression of the TrkB neurotrophin receptor and its ligand, and/or other cytogenetic and molecular abnormalities . However, recurrent disease and poor outcome may also occur in children with tumors lacking these adverse biological features. This suggests that other as yet undefined factors contribute to an aggressive neuroblastoma phenotype.
C-Met is a tyrosine-kinase receptor for hepatocyte growth factor/scatter factor (HGF/SF), and both receptor and ligand are expressed in a number of different tissues [2, 3]. Binding of activated HGF/SF to the extracellular domain of c-Met causes multimerization of the receptor and phosphorylation of tyrosine residues at the juxtamembrane and cytoplasmic regions. This is followed by recruitment and phosphorylation of multiple adaptor proteins, i.e. Grb2, Gab1, SHC, and c-Cbl, as well as activation of signaling molecules such as phosphatidylinositol-3-OH kinase (PI3-K), PLC-γ, STAT3, phospholipase C-γ, Erk 1 and 2, and FAK [4–8]. PI3-K and Erk are necessary not only for c-Met-mediated regulation of cell motility, adhesion, and invasion, but also for control of cell survival (via the Akt pathway) and mitogenesis .
C-Met/HGF/SF signaling is essential for normal cell proliferation, migration, angiogenesis, embryogenesis, organogenesis, and tissue regeneration. Additionally, there is now considerable evidence suggesting that aberrant c-Met/HGF/SF signaling, resulting from mutation or overexpression of the c-Met proto-oncogene and/or its ligand, plays a major role in tumorigenesis, invasion, and metastatic spread in many human tumors [10, 11]. Tumor lines with mutated c-Met or overexpressed c-Met and/or HGF/SF [12–14] are tumorigenic in vitro and in vivo; and tumor cells transfected with c-Met and HGF/SF are capable of forming tumors with an invasive and metastatic phenotype in the nude mice . HGF/SF transgenic mice develop a wide array of mesenchymal- and epithelial-derived tumors which overexpress HGF/SF and c-Met . Similarly, transgenic mice carrying the TPR-MET gene (coding for an oncogenic TPR-MET fusion protein) develop Met-driven T-cell lymphomas . Expression of c-Met and/or HGF has been detected in cell lines established from pediatric tumors including rhabdomyosarcoma, osteogenic sarcoma, and neuroblastoma [12, 18, 19]. Furthermore, abnormal c-Met/HGF/SF signaling has been noted in different types of malignant solid tumors and correlates with advanced stages and poor prognosis [20, 21]. More recently, overepression of c-Met and HGF has also been observed in hematopoietic malignancies, i.e. multiple myeloma and adult T- cell leukemia [22, 23].
Given the oncogenic role of aberrant c-Met/HGF/SF signaling, c-Met has become an attractive therapeutic target [2, 24]. One way to effectively block c-Met signaling is by inhibiting its catalytic activity with small-molecule inhibitors. One such inhibitor is PHA665752, a highly selective c-Met inhibitor which competitively inhibits binding of ATP to the tyrosine kinase domain of c-Met. In vitro, PHA665752 inhibits constitutive and HGF/SF-stimulated c-Met phosphorylation, cell growth, motility, and migration of different tumor cell lines [22, 25–27]. At nanomolar concentrations, it induces massive apoptosis of gastric carcinoma cells with amplified c-Met . In vivo, daily administration of PHA665752 into athymic mice blocked c-Met phosphorylation and caused growth inhibition of tumor xenografts [14, 27].
Phosphatase and tensin homologue (PTEN) is a tumor suppressor protein that modulates several cell functions including proliferation, survival, migration, and tumor-induced angiogenesis mainly by antagonizing PI3K-Akt signaling [29–31]. Mutation or loss of PTEN function has been observed in some cases of NBL and other solid tumors and results in a more aggressive tumor phenotype . In contrast, upregulation of PTEN inhibits proliferation of malignant solid tumor cells in vitro [33, 34].
Studies of the expression and role of c-Met expression in NBL have thus far been limited to cell lines (12, 18,19). We here report for the first time that c-Met is expressed at high levels in advanced-stage, primary NBL tumor tissue. Furthermore, we describe the effects of a small-molecule c-Met inhibitor, PHA665752, on HGF-induced migration and proliferation of NBL cells. We also report the effect of augmented PTEN expression on PHA665752-mediated inhibition of c-Met-HGF/SF signaling in this tumor.
Cell lines and tumor tissue
The human NBL lines SH-EP and SH-SY5Y were used to determine HGF and c-Met gene expression and to assess the effects of PHA665752 (Pfizer) on Met/HGF-induced proliferation and migration of tumor cells. Both cell lines have a single copy of the MYCN oncogene . These cells lines were also chosen because SH-EP expresses c-Met, whereas SH-SY5Y is c-Met negative . Additionally, SH-EP cells show significant proliferative and migratory responses to HGF. SKN-AS served as positive control for HGF expression in qRT-PCR and immunoblot assays. Cells were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Sigma Chemical Co., St. Louis, Mo.). Primary tumor samples were obtained during diagnostic surgery from patients treated at Children's Healthcare of Atlanta hospitals following parental informed consent and Emory University IRB approval. RNA was extracted for quantitative RT-PCR studies of c-Met expression as described below.
SH-SY5Y cells were plated in 6-well plates and transiently transfected with increasing concentrations of full-length human c-Met cDNA in a pMOG vector or vector alone (a kind gift from G. Vande Woude, Van Andel Research Institute, Grand Rapids, MI) using Lipofectamine Plus (Invitrogen, Carlsbad, CA). At 48 hours, cells were washed once with PBS and harvested.
Antibodies and reagents
C-Met inhibitor PHA665752 (Pfizer, Inc., La Jolla, CA) was dissolved in DMSO. LY294002 (in DMSO; Calbiochem) and PD98059 (aqueous solution; Calbiochem) were used at the concentrations described below. Antibodies to c-terminus of c-Met (C-12) and Erk (C-16) were from Santa Cruz Biotechnology (Santa Cruz, CA); p-Erk 1 and 2 (p44/42), p-Akt (Ser473), Akt and phosphospecific c-Met (Tyr 1234/1235) were from Cell Signaling Technology (Beverly, MA); mouse polyclonal HGF antibody was from R&D Systems (Minneapolis, MN). Rosiglitazone, a PPAR-γ agonist and inducer of PTEN, was obtained from Cayman Chemical (Ann Arbor, MI) . Recombinant human HGF was from PeproTech (Rocky Hill, NJ).
Reverse transcription and quantitative real-time polymerase chain reaction (qRT-PCR)
qRT-PCR was used to assay for c-Met and HGF mRNA expression in cell lines, conditioned media, and tumor tissue. Briefly, total RNA from neuroblastoma lines was extracted using the RNAeasy kit (Qiagen, Valencia, CA). The corresponding cDNAs were synthesized by Quantitech Reverse Transcription kit (Qiagen). Quantitative RT-PCR assays for c-Met and HGF were set up with gene specific primers using Quantitect SYBR-Green PCR kit (Qiagen) and executed on a 7500 Real-Time PCR instrument (Applied Biosystems, Foster City, CA). Mean expression values for each mRNA sample were normalized against its GAPDH mRNA level. The c-MET and GAPDH primers were purchased as proprietary SYBR-Green validated primer sets (Qiagen).
The HGF primers were designed by us and synthesized by the Microchemical Facility, Emory University, using the following sequences:
HGF (forward): 5'CTAGATCTTTCCAGTTAATCACACAAC 3'
HGF (reverse): 5'TTCGGAGTCAGTGCCTAAAAGAG 3'
PCR cycling conditions consisted of an initial enzyme activation step at 95° for 15 min followed by a total of 40 cycles including denaturation at 94°C for 15 sec, annealing at 55°C for 30 sec. and final extension at 72°C for 34 sec. The extension step served for fluorescence detection. Detection of gene specific amplicons was verified by dissociation curve analyses. The SH-SY5Y line was designated as the calibrator to quantitate both HGF and c-MET mRNA expression levels.
Cells were plated at 1-104 cells/well in 96-well plates and grown in presence of factors described below. After 72 hours of growth, cells were washed once with PBS and analyzed by the MTT proliferation/viability assay (Invitrogen, Carlsbad, CA). Effects on cell viability were further confirmed by trypan-blue assay. Student's t-test was used to determine significant differences among means for independent proliferation/cell-survival assays performed in triplicate, as well as to evaluate the significance of differences in c-Met expression between stage 3-4 vs stage 1-2 primary tumors.
Cell-migration was assessed using a trans-well chemotaxis assay as previously described [36, 37]. In brief, bottom membranes of transwell chambers of diameter 6.5 mm, 8 um pore size (Costar Corp., Cambridge, MA) were coated with vitronectin (Sigma Chemical Co., St. Louis, Mo) at 10 ug/ml for 1 hour and inserted in 12-well plates. Cells were treated with specific inhibitor (PHA66572 or other inhibitor) for 60 minutes and then washed. Treated cells were plated in equal numbers at 1-2 × 105 in the upper chamber and allowed to migrate across the membrane toward 200 ng/ml HGF (bottom chamber) for 6 hours at 37°C, 5% humidified CO2. Migration was quantified either with 1% crystal violet and manual counting or by automated counting of nuclear-stained cells. Student's t-test was used to determine significant differences among means for independent migration experiments performed in triplicate.
Whole cell lysates were prepared by washing cells once with ice-cold PBS and adding 400 uL of lysis buffer. Protein was quantitated (Bio-Rad Laboratories, Hercules, CA), and equal amounts of protein were resolved by SDS-PAGE and transferred to nitrocellulose. Membranes were blocked with 5% non-fat milk and probed overnight with antisera-specific antibodies at 1:500 dilution. Incubation buffer consisted of either TBST (10 mM Tris [pH 7.6], 50 mM NaCl, and 0.1% Triton X-100) containing 5% non-fat milk or 5% bovine serum albumin (for phosphorylated antibodies). Bound primary antibodies were visualized after washing and probing with appropriate horseradish peroxidase-conjugated detection antibodies at 1:2000 dilution for one hour, using signal-enhanced chemiluminescence (SuperSignal Chemiluminescent substrate, Pierce, Rockford IL). Membranes were stripped and reprobed after washing and blocking. Equal loading was determined by probing for β-actin (Sigma Chemical Co., St. Louis, Mo).
c-Met and HGF expression in NBL cell lines
SH-EP cells expressed significantly more c-Met than did SH-SY5Y cells at both the mRNA and protein level (Figure 1A/B). In contrast, both SH-SY5Y and SH-EP cells were either very low or negative for HGF mRNA, respectively. Both lines lacked detectable HGF protein (Figure 1C/D). Conditioned media from unstimulated and vitronectin-stimulated SH-EP cells did not contain measurable amounts of HGF (data not shown).
PHA665752 inhibits HGF-stimulated migration and proliferation/cell-survival of c-Met-positive neuroblastoma cells
In a semi-quantitative wound-healing assay, we found that SH-EP cells migrated in response to HGF, and this response was greater than that observed with low-c-Met expressing SH-SY5Y cells (data not shown). In the transwell chemotaxis assay, SH-EP cells demonstrated a dose-dependent migration response to HGF (Figure 2A). Transfection experiments showed that only SH-SY5Y cells transfected with c-Met migrated in response to HGF; furthermore, response correlated with the amount of transfected c-Met DNA (Figure 2B). In the MTT-proliferation assay, SH-EP cells showed a proliferative response to HGF in both 72-hr (Figure 2D) and 7-day growth assays (data not shown). PHA665752 inhibited both HGF-mediated migration (Figure 2C) and proliferation/cell-survival (Figure 2D) in a dose-dependent manner. IC50 values for PHA665752-induced inhibition of migration and proliferation ranged from 0.25-0.5 uM.
PHA665752 inhibits c-MET/HGF migration and signaling via the MAPK pathway
PHA665752 completely abrogated HGF-mediated activation of c-Met in SH-EP cells as determined by p-Met(Y1234/1235) levels (Figure 3A); PHA665752 also completely blocked HGF-induced phosphorylation of both MAPK and PI3-K downstream signaling, using p-Erk 1/2 and p-Akt(ser473) levels as surrogate markers, respectively (Figure 3B). Experiments to further characterize the migration-signaling pathways inhibited by PHA665752 showed that PD98059, a MAPK inhibitor, suppressed HGF-activated migration to a similar extent as PHA665752 alone, whereas LY294002, a PI3-K inhibitor, had no effect on migration (Figure 3C).
PTEN induction augments the inhibitory effect of PHA66572 on HGF-mediated proliferation and migration
To evaluate PTEN's ability to potentiate the effects of PHA665752 on c-Met/HGF signaling, we treated SH-EP cells with rosiglitazone, an inducer of PTEN expression . To assess rosiglitazone's effect on proliferation, SH-EP cells were grown in the presence or absence of HGF, with or without rosiglitazone. Rosiglitazone had no effect on SH-EP proliferation in the absence of HGF, although it somewhat reduced HGF-stimulated proliferation (Figure 4A). Importantly, combined PHA665752 and rosiglitazone was significantly (p < .01) more inhibitory for HGF-stimulated SH-EP cell proliferation than was either agent alone HGF (Figure 4A). Furthermore, migration of PHA665752-treated SH-EP cells was significantly reduced when pretreated with rosiglitazone, demonstrating that rosiglitazone augments the migration-inhibitory effects of PHA665752, although the magnitude of this effect was less than that on NBL cell growth (Figure 4B). Rosiglitazone's inhibitory effects on HGF-stimulated proliferation/cell-survival and migration correlated with greater than two-fold inductionof PTEN protein as shown by immunoblotting (Figure 4C).
Expression levels of c-Met mRNA in primary NBL tumor tissue correlates with advanced clinical stage
To evaluate the possible clinical significance of c-Met expression in NBL, we used quantitative RT-PCR to determine c-Met expression levels in mRNA collected from 20 primary neuroblastoma tumors at different clinical stages. Seven tumors were stage 4, five were stage 3, two were stage 2, and six were stage 1. Tumors from patients with more advanced clinical stages (stages 3 and 4) generally had higher c-Met expression levels than did tumors from patients with stages 1 and 2. Four of six stage-4 tumors and one of five stage-3 tumors had c-Met values greater than the corresponding value for SH-EP cells, whereas no stage-1 or 2 tumors had c-Met values in this range (Figure 5).
In this study, we investigated the expression and role of c-Met in NBL. We found that primary tumor cells from patients with clinically aggressive, advanced-stage NBL expressed high-levels of c-Met. Tumor cells from patients with metastatic tumor (stage 4) or locally advanced tumor (stage 3) expressed significantly higher c-Met levels than those from patients with localized disease, i.e. stages 1 and 2. This novel finding strongly suggests that inhibiting c-Met may have therapeutic value in this disease. Accordingly, we chose to test a c-Met inhibitor (PHA665752) with high specificity and potency for blocking c-Met function.
To evaluatethe efficacy of PHA66572 on the migration and proliferation of c-Met expressing NBL cells, we used a c-Met-positive NBL line (SH-EP) as an in vitro model. We found that activation of the c-Met/HGF/SF pathway resulted in increased migration and proliferation-survivalof SH-EP cells but not of c-Met-negative SH-SY5Y cells. This is the first report of the effects of specifically blocking c-Met in NBL cells. Our results agree with those reported by Hecht et al, who showed that exposure of c-Met-expressing NBL cell lines to exogenous HGF resulted in c-Met phosphorylation and induction of migration . These investigators were also able to inhibit migration of NBL cells in Matrigel using an HGF-specific neutralizing antibody and MAPK/ERK inhibitors such as PD98059, respectively. Similarly, Hov et al reported that c-Met activation stimulated both proliferation and migration of myeloma cells in vitro . A role for c-Met in NBL cell migration is further suggested by our finding that HGF triggered migration of SH-SY5Y cells only after transfection with c-Met.
In our experiments to evaluate the effects of PHA665752, we found that this small-molecule inhibitor was able to block HGF-induced phosphorylation of both c-Met and downstream signaling proteins Akt and Erk 1/2 (p44/42). Studies of myeloma and carcinoma cells have yielded similar results [22, 26, 27]. However, in the latter studies, tumor cells were exposed to PHA665752 continuously, whereas in the present study NBL cells were only briefly exposed to low concentrations of this agent. This suggests that NBL cells may be more sensitive to c-Met targeting than some other c-Met expressing tumors.
We also found that PHA665752 showed a marked dose-dependent inhibitory effect on the HGF/c-Met pathway of proliferation and migration in c-Met-expressing NBL cells. These inhibitory effects appeared to be specific for HGF-stimulated proliferation/migration, since PHA665752 had no significant effects on these parameters in the absence of HGF stimulation. Thus, PHA665752 could potentially inhibit HGF-stimulated tumor proliferation/migration resulting from either paracrine (i.e. tumor microenvironment) or autocrine exposure to HGF. Furthermore, brief exposure to PHA665752 completely blocked downstream signaling via the PI3-K/Akt and MAPK/Erk pathways, agreeing with results from studies in several types of carcinoma [25, 27]. Additional studies with MAPK/Erk and PI3-K/Akt pathway-specific inhibitors suggested that PHA665752 can inhibit c-Met/HGF/SF-stimulated migration and proliferation/survival via the MAPK/Erk and PI3-K/Akt pathways, respectively.
Since PHA665752 inhibits the PI3-K/Akt pathway, we hypothesized that its effect might be enhanced by rosiglitazone, an inducer of PTEN expression. Indeed, combined PHA665752 and rosiglitazone induced significantly greater inhibition of both HGF-stimulated proliferation/cell-survival and migration in c-Met-expressing NBL cells than did PHA665752 alone. This finding suggests that the combination of PTEN-inducing agents with small-molecule inhibitors or drugs that block c-Met/HGF/SF signaling may have an augmented anti-tumor effect.
Although we do not expect PHA665752 will be suitable for clinical use due to its tendency to form pulmonary precipitates in animal studies , we believe this agent provides an excellent tool for studying c-Met function in NBL due to its high specificity and activity. Finally, our study supports the notion that c-Met blockade, either through derivatives of PHA665752 with higher bioavailability or through other agents targeting this receptor, deserves further study as a potential therapeutic strategy for NBL.
Elevated c-Met expression is more commonly observed in primary NBL tumor tissue from patients with metastatic tumors. Furthermore, the small-molecule inhibitor PHA665752 is capable of antagonizing HGF-induced migration and proliferation/survival of c-Met-expressing NBL cells, an effect which is enhanced by upregulation of PTEN. These are novel findings in NBL and suggest a therapeutic potential for targeting c-Met in this tumor.
Maris JM, Hogarth MD, Bagatelle R, Cohn SL: Neuroblastoma. Lancet. 2007, 369: 2106-20. 10.1016/S0140-6736(07)60983-0.
Ma PC, Maulik G, Christensen J, Salgia R: c-Met: Structure, functions and potential for therapeutic inhibition. Cancer & Met Rev. 2003, 22: 309-25. 10.1023/A:1023768811842.
Hammond DE, Carter S, Clague MJ: Met receptor dynamics and signalling. Curr Topics Microbiol & Immunol. 2004, 286: 21-44.
Furge KA, Zhang YW, Woude Vande GF: Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 2000, 19: 5582-89. 10.1038/sj.onc.1203859.
Fan S, Ma YX, Gao M, Yuan RQ, Meng Q, Goldberg ID, Rosen EM: The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol & Cell Biol. 2001, 21: 4968-4984. 10.1128/MCB.21.15.4968-4984.2001.
Abounader R, Ranganathan S, Kim BY, Nichols C, Laterra J: Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. J Neurochem. 2001, 76: 1497-508. 10.1046/j.1471-4159.2001.00158.x.
Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, Schaefer E, Parmar K, Salgia R: Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell & Mol Med. 2002, 6: 539-53. 10.1111/j.1582-4934.2002.tb00453.x.
Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt L-G, Miguel RN, Blundell TL, Woude Vande GF, Skoglund U, Svergun DI: Structural basis of hepatocyte growth factor/scatter factor and MET signaling. Proc Natl Acad Sci USA. 2006, 103: 4046-51. 10.1073/pnas.0509040103.
Birchmeier C, Birchmeier W, Gherardi E, Woude Vande GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biology. 2003, 4: 915-25. 10.1038/nrm1261.
Danilkovitch-Miagkova A, Zbar B: Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002, 109: 863-7.
Gao CF, Woude Vande GF: HGF/SF-Met signaling in tumor progression. Cell Res. 2005, 15: 49-51. 10.1038/sj.cr.7290264.
Jankowski K, Kucia M, Wysoczynski M, Reca R, Zhao D, Trzyna E, Trent J, Peiper S, Zembala M, Ratajczak J, Houghton P, Janowska-Wieczorek A, Ratajczak MZ: Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 2003, 63: 7926-35.
Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R: c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003, 63: 6272-8.
Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R: A selective small molecule inhibitor of c-Met, PHA66 inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 5752, 67: 3529-34. 10.1158/0008-5472.CAN-06-4416.
Jeffers M, Rong S, Anver M, Woude Vande GF: Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. Oncogene. 1996, 13: 853-6.
Takayama H, La Rochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G: Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA. 1997, 94: 701-706. 10.1073/pnas.94.2.701.
Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, Dastru W, Christensen JG, Crepaldi T, Ponzetto C: An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors. Clin Cancer Res. 2008, 14: 2220-26. 10.1158/1078-0432.CCR-07-2064.
Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, Cremona O, Campanacci M, Comoglio PM: The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene. 1995, 10: 739-49.
Hecht M, Papoutsi M, Tran HD, Wilting J, Schweigerer L: Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res. 2004, 64: 6109-18. 10.1158/0008-5472.CAN-04-1014.
Cruz J, Reis-Filho JS, Silva P, Lopes JM: Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology. 2003, 65: 72-82. 10.1159/000071207.
Qian C-N, Guo X, Cao B, Kort EJ, Lee C-C, Chen J, Wang L-M, Mai W-Y, Min H-Q, Hong M-H, Woude Vande GF, Resau JH, Teh BT: Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Research. 2002, 62: 589-96.
Hov H, Holt RU, Ro TB, Figural U-M, Mort-Hansen H, Bayou V, Christensen JG, Wage A, Sudan A, Borsht M: A selective c-met inhibitor blocks an autocrine hepatocyte growth factor loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res. 2004, 10: 6686-6694. 10.1158/1078-0432.CCR-04-0874.
Choi YL, Tsakasaki L, O'Neill MC, Yamada Y, Onimaru Y, Matsumoto K, Ohashi J, Yamashita Y, Tsatsumi S, Kaneda R, Takada S, Aburatami H, Kamihira S, Nakamura T, Tononaga M, Mano H: A genomic analysis of adult T-cell leukemia. Oncogene. 2007, 26: 1245-55. 10.1038/sj.onc.1209898.
Christensen JG, Burrows J, Salgia R: c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005, 225: 1-26. 10.1016/j.canlet.2004.09.044.
Chattopadhyay C, El-Naggar AK, Williams MD, Clayman GL: Small Molecule c-Met Inhibitor PHA665752: Effect on Cell Growth and Motility in Papillary Thyroid Carcinoma. Head & Neck. 5752, 30: 991-1000. 10.1002/hed.20816.
Watson GA, Zhang X, Stang MT, Levy RM, Queiroz de Oliverira PE, Gooding WE, Christensen JG, Hughes SJ: Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia. 2006, 8: 949-955. 10.1593/neo.06499.
Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003, 63: 7345-55.
Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA. 2006, 103: 2316-21. 10.1073/pnas.0508776103.
Chung JH, Eng C: Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates cell cycle and apoptosis. Cancer Res. 2005, 65: 8096-100. 10.1158/0008-5472.CAN-05-1888.
Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell. 2000, 100: 387-90. 10.1016/S0092-8674(00)80674-1.
Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL: PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA. 2001, 98: 4622-7. 10.1073/pnas.081063798.
Moritake H, Horii Y, Kuroda H, Sugimoto T: Analysis of PTEN/MMAC1 alteration in neuroblastoma. Cancer Gent & Cytogenet. 2001, 125: 151-5. 10.1016/S0165-4608(00)00378-2.
Farrow B, Evers BM: Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem & Biophys Res Com. 2003, 301: 50-3. 10.1016/S0006-291X(02)02983-2.
Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH: Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol. 2001, 11: 764-8. 10.1016/S0960-9822(01)00225-1.
Ross RA, Biedler JL, Spengler BA: A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors. Cancer Lett. 2003, 197: 35-9. 10.1016/S0304-3835(03)00079-X.
Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh D: CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol. 1998, 140: 961-72. 10.1083/jcb.140.4.961.
Pradip D, Peng X, Durden DL: Rac2 specificity in macrophage integrin signaling: potential role for Syk kinase. J Biol Chem. 2003, 278: 4161-9. 10.1074/jbc.M306491200.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/411/prepub
This work was supported by grants from CURE Childhood Cancer, the Emory-Egleston Children's Research Council, the Georgia Cancer Coalition, and CA94233 from the NIH. H.E.C was the recipient of a CURE Childhood Cancer Fellowship award
One of the co-authors (JGC) is employed by Pfizer, which provided the drug under study (PHA665752).
HEC, HWF, and CSA designed the study and wrote the manuscript. HEC also performed the migration, proliferation and transfection experiments with the assistance of TW, DLD and PD. AD grew the cell lines and performed qRT-PCR studies on tumor tissue, as well as assisted in MTT/viability assays for proliferation/cell-survival. JGC kindly provided PHA665752 and advice regarding experimental design. All authors read and approved the manuscript.
About this article
Cite this article
Crosswell, H.E., Dasgupta, A., Alvarado, C.S. et al. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer 9, 411 (2009). https://doi.org/10.1186/1471-2407-9-411
- PTEN Expression
- MYCN Oncogene Amplification
- Transwell Chemotaxis Assay